Drug factory · FDA FEI 2513291

Eurofins Lancaster Laboratories, LLC

2425 New Holland Pike, Lancaster, PA, United States

United States: 1

Problems found, fixed voluntarily at FDA's last inspection, Aug 26, 2025.

Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.

8 drug inspections on record since 2009: 6 with no problems, 2 with problems fixed voluntarily, 0 with FDA action.

What it does, for whom

DrugRoleForNDC
AfliberceptTests it Regeneron Pharmaceuticals, Inc. 61755-005
AlirocumabTests it Regeneron Pharmaceuticals, Inc. 61755-020, 61755-021
AzithromycinTests it Pfizer Laboratories Div Pfizer Inc 0069-3051, 0069-3080
BuprenorphineTests it Indivior Inc. 12496-0100, 12496-0300
Ciltacabtagene AutoleucelTests it Janssen Biotech, Inc. 57894-111
ClonidineTests it Mayne Pharma Inc. 51862-453, 51862-454, 51862-455
Cx-055611Tests it Moderna US, Inc. 80777-114, 80777-115
Cytarabine and DaunorubicinTests it Jazz Pharmaceuticals, Inc. 68727-745
Daratumumab and Hyaluronidase (human Recombinant)Tests it Janssen Biotech, Inc. 57894-503
Efanesoctocog AlfaTests it Bioverativ Therapeutics Inc. 71104-978, 71104-979, 71104-981 +3
Efbemalenograstim AlfaTests it Acrotech Biopharma Inc 72893-016
EsmololTests it Hikma Pharmaceuticals USA Inc. 0641-2965
Hydrochlorothiazide and IrbesartanTests it Sanofi-Aventis U.S. LLC 0024-5855, 0024-5856
IrbesartanTests it Sanofi-Aventis U.S. LLC 0024-5851, 0024-5852
IxazomibTests it Takeda Pharmaceuticals America, Inc. 63020-230, 63020-390, 63020-400
LevoketoconazoleTests it Xeris Pharmaceuticals, Inc. 72065-003
LonafarnibTests it Eiger BioPharmaceuticals, Inc. 73079-050, 73079-075
Lunsotogene ParvecTests it Regeneron Pharmaceuticals, Inc. 61755-062
MebrofeninTests it Bracco Diagnostics Inc. 0270-0083
OxcarbazepineTests it Ajanta Pharma USA Inc. 27241-304, 27241-305, 27241-306
PegcetacoplanTests it Apellis Pharmaceuticals, Inc. 73606-010, 73606-020
PeramivirTests it BioCryst Pharmaceuticals, Inc., Seqirus USA Inc. 72769-181, 61364-181
PlazomicinTests it Cipla Therapeutics Inc., Cipla USA., Inc. 80735-820, 69097-820
RisperidoneTests it Indivior Inc. 12496-0090, 12496-0120
TolvaptanTests it Otsuka America Pharmaceutical, Inc. 59148-079, 59148-080, 59148-082 +4

FDA inspection history

EndedResultProgramProblems noted
Aug 26, 2025Problems found, fixed voluntarilyDrug Quality Assurance2
Oct 17, 2019No problems foundDrug Quality Assurance—
Sep 28, 2017No problems foundDrug Quality Assurance—
Jun 19, 2015No problems foundDrug Quality Assurance—
Jun 27, 2013No problems foundDrug Quality Assurance—
May 17, 2012No problems foundDrug Quality Assurance—
Sep 7, 2010Problems found, fixed voluntarilyDrug Quality Assurance1
Oct 6, 2009No problems foundDrug Quality Assurance—

What inspectors wrote down

From FDA's Form 483 citations: conditions an investigator observed that may violate drug manufacturing rules, as FDA published them.

Aug 26, 2025 inspection

Sep 7, 2010 inspection

Registered with FDA for: analysis.